APO Research
Talk to an analyst

APO RESEARCH · REPORT

Herpes Labialis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Herpes Labialis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025193 pages

Choose your research edition.

Industry ResearchHerpes Labialis Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Herpes Labialis Drugs Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Herpes Labialis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Herpes Labialis Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Herpes Labialis Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Herpes Labialis Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Herpes Labialis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Herpes Labialis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Herpes Labialis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Herpes Labialis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Herpes Labialis Drugs include GSK, Teva, Novartis, Mylan, Livzon, Bayer, Med Shine, Hikma and Daewoong Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Herpes Labialis Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Herpes Labialis Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Herpes Labialis Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Herpes Labialis Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Herpes Labialis Drugs Segment by Company

GSK

Teva

Novartis

Mylan

Livzon

Bayer

Med Shine

Hikma

Daewoong Pharmaceutical

Cipher

Carmex

Cadila

Blistex

Apotex

Herpes Labialis Drugs Segment by Type

Aciclovir

Docosanol

Famciclovir

Valacyclovir

Other

Herpes Labialis Drugs Segment by Application

Injection

External Use

Oral

Herpes Labialis Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Herpes Labialis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Herpes Labialis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Herpes Labialis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Herpes Labialis Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Herpes Labialis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Herpes Labialis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Herpes Labialis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Herpes Labialis Drugs Industry Trends Table 2. Herpes Labialis Drugs Industry Drivers Table 3. Herpes Labialis Drugs Industry Opportunities and Challenges Table 4. Herpes Labialis Drugs Industry Restraints Table 5. Global Herpes Labialis Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Herpes Labialis Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Herpes Labialis Drugs Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Herpes Labialis Drugs Sales Market Share by Manufacturers Table 9. Global Herpes Labialis Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Herpes Labialis Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Herpes Labialis Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Herpes Labialis Drugs Manufacturers, Product Type & Application Table 13. Global Herpes Labialis Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Herpes Labialis Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Aciclovir Table 17. Major Manufacturers of Docosanol Table 18. Major Manufacturers of Famciclovir Table 19. Major Manufacturers of Valacyclovir Table 20. Major Manufacturers of Other Table 21. Global Herpes Labialis Drugs Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 22. Global Herpes Labialis Drugs Sales by Type (2021-2026) & (W Units) Table 23. Global Herpes Labialis Drugs Sales by Type (2027-2032) & (W Units) Table 24. Global Herpes Labialis Drugs Sales Market Share by Type (2021-2026) Table 25. Global Herpes Labialis Drugs Sales Market Share by Type (2027-2032) Table 26. Global Herpes Labialis Drugs Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 27. Global Herpes Labialis Drugs Revenue by Type (2021-2026) & (W Units) Table 28. Global Herpes Labialis Drugs Revenue by Type (2027-2032) & (W Units) Table 29. Global Herpes Labialis Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Herpes Labialis Drugs Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Injection Table 32. Major Manufacturers of External Use Table 33. Major Manufacturers of Oral Table 34. Global Herpes Labialis Drugs Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 35. Global Herpes Labialis Drugs Sales by Application (2021-2026) & (W Units) Table 36. Global Herpes Labialis Drugs Sales by Application (2027-2032) & (W Units) Table 37. Global Herpes Labialis Drugs Sales Market Share by Application (2021-2026) Table 38. Global Herpes Labialis Drugs Sales Market Share by Application (2027-2032) Table 39. Global Herpes Labialis Drugs Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 40. Global Herpes Labialis Drugs Revenue by Application (2021-2026) & (W Units) Table 41. Global Herpes Labialis Drugs Revenue by Application (2027-2032) & (W Units) Table 42. Global Herpes Labialis Drugs Revenue Market Share by Application (2021-2026) Table 43. Global Herpes Labialis Drugs Revenue Market Share by Application (2027-2032) Table 44. Global Herpes Labialis Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 45. Global Herpes Labialis Drugs Sales by Region (2021-2026) & (W Units) Table 46. Global Herpes Labialis Drugs Sales Market Share by Region (2021-2026) Table 47. Global Herpes Labialis Drugs Sales Forecasted by Region (2027-2032) & (W Units) Table 48. Global Herpes Labialis Drugs Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Herpes Labialis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 50. North America Herpes Labialis Drugs Sales by Country (2021-2026) & (W Units) Table 51. North America Herpes Labialis Drugs Sales by Country (2027-2032) & (W Units) Table 52. Europe Herpes Labialis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 53. Europe Herpes Labialis Drugs Sales by Country (2021-2026) & (W Units) Table 54. Europe Herpes Labialis Drugs Sales by Country (2027-2032) & (W Units) Table 55. Asia Pacific Herpes Labialis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 56. Asia Pacific Herpes Labialis Drugs Sales by Country (2021-2026) & (W Units) Table 57. Asia Pacific Herpes Labialis Drugs Sales by Country (2027-2032) & (W Units) Table 58. South America, Middle East and Africa Herpes Labialis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 59. South America, Middle East and Africa Herpes Labialis Drugs Sales by Country (2021-2026) & (W Units) Table 60. South America, Middle East and Africa Herpes Labialis Drugs Sales by Country (2027-2032) & (W Units) Table 61. Global Herpes Labialis Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Herpes Labialis Drugs Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Herpes Labialis Drugs Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Herpes Labialis Drugs Revenue Market Share by Region (2021-2026) Table 65. Global Herpes Labialis Drugs Revenue Market Share by Region (2027-2032) Table 66. GSK Company Information Table 67. GSK Business Overview Table 68. GSK Herpes Labialis Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. GSK Herpes Labialis Drugs Product Portfolio Table 70. GSK Recent Development Table 71. Teva Company Information Table 72. Teva Business Overview Table 73. Teva Herpes Labialis Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Teva Herpes Labialis Drugs Product Portfolio Table 75. Teva Recent Development Table 76. Novartis Company Information Table 77. Novartis Business Overview Table 78. Novartis Herpes Labialis Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Novartis Herpes Labialis Drugs Product Portfolio Table 80. Novartis Recent Development Table 81. Mylan Company Information Table 82. Mylan Business Overview Table 83. Mylan Herpes Labialis Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Mylan Herpes Labialis Drugs Product Portfolio Table 85. Mylan Recent Development Table 86. Livzon Company Information Table 87. Livzon Business Overview Table 88. Livzon Herpes Labialis Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Livzon Herpes Labialis Drugs Product Portfolio Table 90. Livzon Recent Development Table 91. Bayer Company Information Table 92. Bayer Business Overview Table 93. Bayer Herpes Labialis Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Bayer Herpes Labialis Drugs Product Portfolio Table 95. Bayer Recent Development Table 96. Med Shine Company Information Table 97. Med Shine Business Overview Table 98. Med Shine Herpes Labialis Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Med Shine Herpes Labialis Drugs Product Portfolio Table 100. Med Shine Recent Development Table 101. Hikma Company Information Table 102. Hikma Business Overview Table 103. Hikma Herpes Labialis Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Hikma Herpes Labialis Drugs Product Portfolio Table 105. Hikma Recent Development Table 106. Daewoong Pharmaceutical Company Information Table 107. Daewoong Pharmaceutical Business Overview Table 108. Daewoong Pharmaceutical Herpes Labialis Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Daewoong Pharmaceutical Herpes Labialis Drugs Product Portfolio Table 110. Daewoong Pharmaceutical Recent Development Table 111. Cipher Company Information Table 112. Cipher Business Overview Table 113. Cipher Herpes Labialis Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Cipher Herpes Labialis Drugs Product Portfolio Table 115. Cipher Recent Development Table 116. Carmex Company Information Table 117. Carmex Business Overview Table 118. Carmex Herpes Labialis Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Carmex Herpes Labialis Drugs Product Portfolio Table 120. Carmex Recent Development Table 121. Cadila Company Information Table 122. Cadila Business Overview Table 123. Cadila Herpes Labialis Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Cadila Herpes Labialis Drugs Product Portfolio Table 125. Cadila Recent Development Table 126. Blistex Company Information Table 127. Blistex Business Overview Table 128. Blistex Herpes Labialis Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Blistex Herpes Labialis Drugs Product Portfolio Table 130. Blistex Recent Development Table 131. Apotex Company Information Table 132. Apotex Business Overview Table 133. Apotex Herpes Labialis Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Apotex Herpes Labialis Drugs Product Portfolio Table 135. Apotex Recent Development Table 136. Key Raw Materials Table 137. Raw Materials Key Suppliers Table 138. Herpes Labialis Drugs Distributors List Table 139. Herpes Labialis Drugs Customers List Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. Herpes Labialis Drugs Product Image Figure 2. Global Herpes Labialis Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Herpes Labialis Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Herpes Labialis Drugs Sales (2021-2032) & (W Units) Figure 5. Global Herpes Labialis Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Herpes Labialis Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Aciclovir Image Figure 9. Docosanol Image Figure 10. Famciclovir Image Figure 11. Valacyclovir Image Figure 12. Other Image Figure 13. Global Herpes Labialis Drugs Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Herpes Labialis Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Herpes Labialis Drugs Sales Market Share by Type (2021-2032) Figure 16. Global Herpes Labialis Drugs Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 17. Global Herpes Labialis Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Herpes Labialis Drugs Revenue Market Share by Type (2021-2032) Figure 19. Injection Image Figure 20. External Use Image Figure 21. Oral Image Figure 22. Global Herpes Labialis Drugs Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 23. Global Herpes Labialis Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Herpes Labialis Drugs Sales Market Share by Application (2021-2032) Figure 25. Global Herpes Labialis Drugs Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 26. Global Herpes Labialis Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Herpes Labialis Drugs Revenue Market Share by Application (2021-2032) Figure 28. North America Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 29. North America Herpes Labialis Drugs Sales Market Share by Country (2021-2032) Figure 30. U.S. Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 31. Canada Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Mexico Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Europe Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Europe Herpes Labialis Drugs Sales Market Share by Country (2021-2032) Figure 35. Germany Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 36. France Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 37. U.K. Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 38. Italy Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Netherlands Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Asia Pacific Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Asia Pacific Herpes Labialis Drugs Sales Market Share by Country (2021-2032) Figure 42. China Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 43. Japan Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 44. South Korea Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 45. Southeast Asia Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 46. India Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 47. Australia Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 48. South America, Middle East and Africa Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 49. South America, Middle East and Africa Herpes Labialis Drugs Sales Market Share by Country (2021-2032) Figure 50. Brazil Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 51. South Africa Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 52. Saudi Arabia Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Turkey Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Argentina Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 55. UAE Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Egypt Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Chile Herpes Labialis Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Global Herpes Labialis Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Herpes Labialis Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Herpes Labialis Drugs Revenue (2021-2032) & (US$ Million) Figure 61. North America Herpes Labialis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Herpes Labialis Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Europe Herpes Labialis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Herpes Labialis Drugs Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Herpes Labialis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Herpes Labialis Drugs Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Herpes Labialis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Herpes Labialis Drugs Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Herpes Labialis Drugs Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Aciclovir
  • Docosanol
  • Famciclovir
  • Valacyclovir
  • Other
Applications
  • Injection
  • External Use
  • Oral
Companies covered
  • GSK
  • Teva
  • Novartis
  • Mylan
  • Livzon
  • Bayer
  • Med Shine
  • Hikma
  • Daewoong Pharmaceutical
  • Cipher
  • Carmex
  • Cadila
  • Blistex
  • Apotex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Herpes Labialis Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Herpes Labialis Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Herpes Labialis Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Herpes Labialis Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Herpes Labialis Drugs Market Dynamics
  1. 2.1 Herpes Labialis Drugs Industry Trends
  2. 2.2 Herpes Labialis Drugs Industry Drivers
  3. 2.3 Herpes Labialis Drugs Industry Opportunities and Challenges
  4. 2.4 Herpes Labialis Drugs Industry Restraints
3 Herpes Labialis Drugs Market by Manufacturers
  1. 3.1 Global Herpes Labialis Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Herpes Labialis Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Herpes Labialis Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Herpes Labialis Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Herpes Labialis Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Herpes Labialis Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Herpes Labialis Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Herpes Labialis Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Herpes Labialis Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Herpes Labialis Drugs Tier 1, Tier 2, and Tier 3
4 Herpes Labialis Drugs Market by Type
  1. 4.1 Herpes Labialis Drugs Type Introduction
  2. 4.1.1 Aciclovir
  3. 4.1.2 Docosanol
  4. 4.1.3 Famciclovir
  5. 4.1.4 Valacyclovir
  6. 4.1.5 Other
  7. 4.2 Global Herpes Labialis Drugs Sales by Type
  8. 4.2.1 Global Herpes Labialis Drugs Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Herpes Labialis Drugs Sales by Type (2021-2032)
  10. 4.2.3 Global Herpes Labialis Drugs Sales Market Share by Type (2021-2032)
  11. 4.3 Global Herpes Labialis Drugs Revenue by Type
  12. 4.3.1 Global Herpes Labialis Drugs Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Herpes Labialis Drugs Revenue by Type (2021-2032)
  14. 4.3.3 Global Herpes Labialis Drugs Revenue Market Share by Type (2021-2032)
5 Herpes Labialis Drugs Market by Application
  1. 5.1 Herpes Labialis Drugs Application Introduction
  2. 5.1.1 Injection
  3. 5.1.2 External Use
  4. 5.1.3 Oral
  5. 5.2 Global Herpes Labialis Drugs Sales by Application
  6. 5.2.1 Global Herpes Labialis Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Herpes Labialis Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Herpes Labialis Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Herpes Labialis Drugs Revenue by Application
  10. 5.3.1 Global Herpes Labialis Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Herpes Labialis Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Herpes Labialis Drugs Revenue Market Share by Application (2021-2032)
6 Global Herpes Labialis Drugs Sales by Region
  1. 6.1 Global Herpes Labialis Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Herpes Labialis Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Herpes Labialis Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Herpes Labialis Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Herpes Labialis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Herpes Labialis Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Herpes Labialis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Herpes Labialis Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Herpes Labialis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Herpes Labialis Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Herpes Labialis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Herpes Labialis Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Herpes Labialis Drugs Revenue by Region
  1. 7.1 Global Herpes Labialis Drugs Revenue by Region
  2. 7.1.1 Global Herpes Labialis Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Herpes Labialis Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Herpes Labialis Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Herpes Labialis Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Herpes Labialis Drugs Revenue (2021-2032)
  8. 7.2.2 North America Herpes Labialis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Herpes Labialis Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Herpes Labialis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Herpes Labialis Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Herpes Labialis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Herpes Labialis Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Herpes Labialis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Herpes Labialis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GSK Herpes Labialis Drugs Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Herpes Labialis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Herpes Labialis Drugs Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Herpes Labialis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Herpes Labialis Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Mylan
  20. 8.4.1 Mylan Company Information
  21. 8.4.2 Mylan Business Overview
  22. 8.4.3 Mylan Herpes Labialis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Herpes Labialis Drugs Product Portfolio
  24. 8.4.5 Mylan Recent Developments
  25. 8.5 Livzon
  26. 8.5.1 Livzon Company Information
  27. 8.5.2 Livzon Business Overview
  28. 8.5.3 Livzon Herpes Labialis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Livzon Herpes Labialis Drugs Product Portfolio
  30. 8.5.5 Livzon Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer Herpes Labialis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bayer Herpes Labialis Drugs Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 Med Shine
  38. 8.7.1 Med Shine Company Information
  39. 8.7.2 Med Shine Business Overview
  40. 8.7.3 Med Shine Herpes Labialis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Med Shine Herpes Labialis Drugs Product Portfolio
  42. 8.7.5 Med Shine Recent Developments
  43. 8.8 Hikma
  44. 8.8.1 Hikma Company Information
  45. 8.8.2 Hikma Business Overview
  46. 8.8.3 Hikma Herpes Labialis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Hikma Herpes Labialis Drugs Product Portfolio
  48. 8.8.5 Hikma Recent Developments
  49. 8.9 Daewoong Pharmaceutical
  50. 8.9.1 Daewoong Pharmaceutical Company Information
  51. 8.9.2 Daewoong Pharmaceutical Business Overview
  52. 8.9.3 Daewoong Pharmaceutical Herpes Labialis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Daewoong Pharmaceutical Herpes Labialis Drugs Product Portfolio
  54. 8.9.5 Daewoong Pharmaceutical Recent Developments
  55. 8.10 Cipher
  56. 8.10.1 Cipher Company Information
  57. 8.10.2 Cipher Business Overview
  58. 8.10.3 Cipher Herpes Labialis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Cipher Herpes Labialis Drugs Product Portfolio
  60. 8.10.5 Cipher Recent Developments
  61. 8.11 Carmex
  62. 8.11.1 Carmex Company Information
  63. 8.11.2 Carmex Business Overview
  64. 8.11.3 Carmex Herpes Labialis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Carmex Herpes Labialis Drugs Product Portfolio
  66. 8.11.5 Carmex Recent Developments
  67. 8.12 Cadila
  68. 8.12.1 Cadila Company Information
  69. 8.12.2 Cadila Business Overview
  70. 8.12.3 Cadila Herpes Labialis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Cadila Herpes Labialis Drugs Product Portfolio
  72. 8.12.5 Cadila Recent Developments
  73. 8.13 Blistex
  74. 8.13.1 Blistex Company Information
  75. 8.13.2 Blistex Business Overview
  76. 8.13.3 Blistex Herpes Labialis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Blistex Herpes Labialis Drugs Product Portfolio
  78. 8.13.5 Blistex Recent Developments
  79. 8.14 Apotex
  80. 8.14.1 Apotex Company Information
  81. 8.14.2 Apotex Business Overview
  82. 8.14.3 Apotex Herpes Labialis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Apotex Herpes Labialis Drugs Product Portfolio
  84. 8.14.5 Apotex Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Herpes Labialis Drugs Value Chain Analysis
  2. 9.1.1 Herpes Labialis Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Herpes Labialis Drugs Production Mode & Process
  6. 9.2 Herpes Labialis Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Herpes Labialis Drugs Distributors
  9. 9.2.3 Herpes Labialis Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst